
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more…
In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy
and the health sciences; In-silico modeling and real-word outcomes; and more…






